{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T17:51:15Z","timestamp":1791049875605,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005703","name":"Akdeniz University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005703","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Aim<\/jats:title>\n                <jats:p>The study aims to determine the physiological and pathophysiological distribution of the radiopharmaceutical (Ga<jats:sup>68<\/jats:sup>-PSMA-617) and investigate whether there are differences in distribution according to the laboratory, histopathological and clinical findings that can affect image evaluation. Also, we aimed to determine cut-off values to distinguish physiological and pathological uptake in prostate, bone, and lymph nodes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and Methods<\/jats:title>\n                <jats:p>229 prostate cancer patients who underwent Ga<jats:sup>68<\/jats:sup>-PSMA PET\/CT at our department were retrospectively analyzed. The patients were grouped according to PET\/CT results, Gleason scores, PSA values, received treatments, metastatic status and other laboratory values. The SUV values of the organs, tissues, and pathological lesions of the patients in these subgroups were compared among themselves.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>No significant difference was detected in the physiological uptake of lymph nodes and bone between the groups. In the group with patients that received androgen deprivation therapy (ADT), the bone metastasis SUV values were found to be higher and the SUV values of the submandibular gland and renal cortex were found to be lower (Mann\u2013Whitney <jats:italic>U<\/jats:italic>, <jats:italic>p<\/jats:italic>\u2009=\u20090.043; 0.004; 0.01, respectively). In the group with patients who received radiotherapy, the normal prostate tissue SUV values were determined to be higher (Mann\u2013Whitney <jats:italic>U<\/jats:italic>, <jats:italic>p<\/jats:italic>\u2009=\u20090.009). The SUV values of the submandibular gland, muscle, liver, and blood pool were found to be lower in the group of patients with high serum LDH values. The cut-off SUVmax value was determined to be 6.945 (sensitivity 89.6%, specificity 98.1%) for primary prostate lesion; 4.72 for lymph node metastasis; 4.25 for bone metastasis. The serum PSA cut-off value to distinguish the negative\/positive groups was found to be 1,505 (sensitivity 79.7%, specificity 77.3%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In conclusion, PSMA-617 demonstrates a similar biodistribution with other PSMA ligands. The physiological uptake of lymph nodes and bone which are mostly metastasized in prostate cancer, are not affected by the factors we examined. It should be kept in mind that the normal prostate tissue uptake may increase in patients receiving radiotherapy, and the physiological\/pathological uptake of the organs may differ due to the changes in PSMA expression in patients receiving ADT, tumor burden, and kidney function may affect the biodistribution.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12149-024-01957-x","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T13:02:12Z","timestamp":1720530132000},"page":"894-903","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Physiological biodistribution on Ga68-PSMA PET\/CT and the factors effecting biodistribution"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6020-1398","authenticated-orcid":false,"given":"Ay\u00e7a","family":"Ar\u00e7ay \u00d6zt\u00fcrk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Metin","family":"Erk\u0131l\u0131\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonca G\u00fcl","family":"Bural","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Funda","family":"Ayd\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adil","family":"Boz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,9]]},"reference":[{"issue":"3","key":"1957_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"1957_CR2","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0090-4295(98)00278-7","volume":"52","author":"SD Sweat","year":"1998","unstructured":"Sweat SD, et al. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. 1998;52(4):637\u201340.","journal-title":"Urology"},{"issue":"3","key":"1957_CR3","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/s11307-016-0945-x","volume":"18","author":"V Prasad","year":"2016","unstructured":"Prasad V, et al. Biodistribution of [(68)Ga]PSMA-HBED-CC in patients with prostate cancer: characterization of uptake in normal organs and tumour lesions. Mol Imaging Biol. 2016;18(3):428\u201336.","journal-title":"Mol Imaging Biol"},{"issue":"11","key":"1957_CR4","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1097\/MNM.0000000000000566","volume":"37","author":"E Demirci","year":"2016","unstructured":"Demirci E, et al. Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET\/CT imaging. Nucl Med Commun. 2016;37(11):1169\u201379.","journal-title":"Nucl Med Commun"},{"key":"1957_CR5","doi-asserted-by":"crossref","unstructured":"F O. Assessment of Physiological Distribution and Normal Variants of 68Ga PSMA-I&T PET\/CT. European Archives of Medical Research. 2018;34(2):235\u2013242.","DOI":"10.5152\/eamr.2018.24865"},{"issue":"6","key":"1957_CR6","doi-asserted-by":"publisher","first-page":"914","DOI":"10.2967\/jnumed.114.147413","volume":"56","author":"M Bene\u0161ov\u00e1","year":"2015","unstructured":"Bene\u0161ov\u00e1 M, et al. Preclinical evaluation of a tailor-made DOTA-conjugated psma inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med. 2015;56(6):914\u201320.","journal-title":"J Nucl Med"},{"issue":"11","key":"1957_CR7","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.2967\/jnumed.115.161299","volume":"56","author":"A Afshar-Oromieh","year":"2015","unstructured":"Afshar-Oromieh A, et al. The theranostic PSMA Ligand PSMA-617 in the diagnosis of prostate cancer by PET\/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J Nucl Med. 2015;56(11):1697\u2013705.","journal-title":"J Nucl Med"},{"issue":"2","key":"1957_CR8","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/S0090-4295(96)00184-7","volume":"48","author":"G Wright","year":"1996","unstructured":"Wright G, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology. 1996;48(2):326\u201334.","journal-title":"Urology"},{"issue":"1","key":"1957_CR9","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2967\/jnumed.116.181800","volume":"58","author":"TA Hope","year":"2017","unstructured":"Hope TA, et al. 68 Ga-PSMA-11 PET Imaging of response to androgen receptor inhibition: first human experience. J Nucl Med. 2017;58(1):81\u20134.","journal-title":"J Nucl Med"},{"issue":"1","key":"1957_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00259-019-04529-8","volume":"47","author":"S Vaz","year":"2020","unstructured":"Vaz S, et al. Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients. Eur J Nucl Med Mol Imaging. 2020;47(1):9\u201315.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"1957_CR11","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00259-019-04635-7","volume":"47","author":"O Ettala","year":"2020","unstructured":"Ettala O, et al. Prospective study on the effect of short-term androgen deprivation therapy on PSMA uptake evaluated with 68Ga-PSMA-11 PET\/MRI in men with treatment-na\u00efve prostate cancer. Eur J Nucl Med Mol Imaging. 2020;47(3):665\u201373.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"1957_CR12","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S1879-5226(10)60038-3","volume":"21","author":"Hwang","year":"2010","unstructured":"Hwang, et al. The effects of medical castration on testes in patients with advanced prostate cancer. Urol Sci. 2010;21(3):169\u201374.","journal-title":"Urol Sci"},{"issue":"10","key":"1957_CR13","doi-asserted-by":"publisher","first-page":"14083","DOI":"10.1007\/s13277-016-5228-2","volume":"37","author":"R Liu","year":"2016","unstructured":"Liu R, et al. Overall survival of cancer patients with serum lactate dehydrogenase greater than 1000 IU\/L. Tumor Biol. 2016;37(10):14083\u20138.","journal-title":"Tumor Biol"},{"issue":"33","key":"1957_CR14","doi-asserted-by":"publisher","first-page":"55094","DOI":"10.18632\/oncotarget.19049","volume":"8","author":"F Gaertner","year":"2017","unstructured":"Gaertner F, et al. Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer. Oncotarget. 2017;8(33):55094\u2013103.","journal-title":"Oncotarget"},{"issue":"6","key":"1957_CR15","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00259-017-3631-6","volume":"44","author":"C Uprimny","year":"2017","unstructured":"Uprimny C, et al. 68Ga-PSMA-11 PET\/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. Eur J Nucl Med Mol Imaging. 2017;44(6):941\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"1957_CR16","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1007\/s12149-020-01529-9","volume":"34","author":"M Caglar","year":"2020","unstructured":"Caglar M, et al. Bone scintigraphy as a gatekeeper for the detection of bone metastases in patients with prostate cancer: comparison with Ga-68 PSMA PET\/CT. Ann Nucl Med. 2020;34(12):932\u201341.","journal-title":"Ann Nucl Med"},{"issue":"11","key":"1957_CR17","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.2967\/jnumed.116.172627","volume":"57","author":"WP Fendler","year":"2016","unstructured":"Fendler WP, et al. 68Ga-PSMA PET\/CT Detects the location and extent of primary prostate cancer. J Nucl Med. 2016;57(11):1720\u20135.","journal-title":"J Nucl Med"},{"issue":"8","key":"1957_CR18","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1007\/s00259-015-3078-6","volume":"42","author":"F Ceci","year":"2015","unstructured":"Ceci F, et al. 8Ga-PSMA PET\/CT for restaging recurrent prostate cancer: which factors are associated with PET\/CT detection rate? Eur J Nucl Med Mol Imaging. 2015;42(8):1284\u201394.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"1957_CR19","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00259-014-2949-6","volume":"42","author":"A Afshar-Oromieh","year":"2015","unstructured":"Afshar-Oromieh A, et al. The diagnostic value of PET\/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42(2):197\u2013209.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"1957_CR20","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.2967\/jnumed.117.190314","volume":"58","author":"S Koerber","year":"2017","unstructured":"Koerber S, et al. 68 Ga-PSMA-11 PET\/CT in Newly diagnosed carcinoma of the prostate: correlation of intraprostatic PSMA uptake with several clinical parameters. J Nucl Med. 2017;58(12):1943\u20138.","journal-title":"J Nucl Med"},{"issue":"5","key":"1957_CR21","doi-asserted-by":"publisher","first-page":"668","DOI":"10.2967\/jnumed.115.154153","volume":"56","author":"M Eiber","year":"2015","unstructured":"Eiber M, et al. Evaluation of hybrid 68Ga-PSMA ligand PET\/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56(5):668\u201374.","journal-title":"J Nucl Med"},{"issue":"8","key":"1957_CR22","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s12149-017-1207-y","volume":"31","author":"Y Sanli","year":"2017","unstructured":"Sanli Y, et al. Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET\/CT in patients with recurrent prostate cancer. Ann Nucl Med. 2017;31(8):709\u201317.","journal-title":"Ann Nucl Med"},{"issue":"4","key":"1957_CR23","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1007\/s11307-019-01445-z","volume":"22","author":"H Dadgar","year":"2020","unstructured":"Dadgar H, et al. Application of [68Ga]PSMA PET\/CT in diagnosis and management of prostate cancer patients. Mol Imaging Biol. 2020;22(4):1062\u20139.","journal-title":"Mol Imaging Biol"},{"issue":"8","key":"1957_CR24","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1007\/s00259-017-3711-7","volume":"44","author":"A Afshar-Oromieh","year":"2017","unstructured":"Afshar-Oromieh A, et al. Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET\/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging. 2017;44(8):1258\u201368.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"1957_CR25","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","volume":"40","author":"A Afshar-Oromieh","year":"2013","unstructured":"Afshar-Oromieh A, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40(4):486\u201395.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-024-01957-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-024-01957-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-024-01957-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T23:06:13Z","timestamp":1729292773000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-024-01957-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1957"],"URL":"https:\/\/doi.org\/10.1007\/s12149-024-01957-x","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,9]]},"assertion":[{"value":"3 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}